Shopping Cart
- Remove All
- Your shopping cart is currently empty
In hematological malignancies, CD19, BCMA, and CD22 are the most frequently studied target proteins. CD19 is the primary target for the treatment of B-cell blood cancers. BCMA and CD22 are both antigens expressed on the surface of B cells, and cell therapies targeting these two targets could be used to treat patients with B-cell blood cancers that have developed resistance to cell therapies targeting CD19. Other related targets under study include GPRC5D, CLEC12A and CD7.
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.